about
Sensitivity analysis of longitudinal binary quality of life data with drop-out: an example using the EORTC QLQ-C30.Analysing longitudinal continuous quality of life data with dropout.Incomplete quality of life data in randomized trials: missing items.Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955).Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.Retrospective analysis of results of p(65)+Be neutron therapy for treatment of prostate adenocarcinoma at the cyclotron of Louvain-la-Leuve. Part II: Side effects and their influence on quality of life measured with QLQ-C30 of EORTC.The temporal impact of aging on the burden of herpes zoster.Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC Gynaecological Cancer Cooperative Group study.Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.The impact of assumptions regarding vaccine-induced immunity on the public health and cost-effectiveness of hepatitis A vaccination: Is one dose sufficient?Budget constraint and vaccine dosing: a mathematical modelling exercise.Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.Vaccine Timeliness: A Cost Analysis of the Potential Implications of Delayed Pertussis Vaccination in the US.Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial.Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia in Adults 60 Years of Age or Older: Results from a Prospective, Physician Practice-Based Cohort Study in Kushiro, Japan.Assessment of the Potential Herpes Zoster and Post Herpetic Neuralgia Case Avoidance with Vaccination in the United States.Strategies to fit pattern-mixture models.Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study.Prognostic factors for survival in adult patients with cerebral low-grade glioma.Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer.Response to publications by Heyward W et al. and Kuan R et al.: Clinical and cost-effectiveness analyses, respectively, of hepatitis B vaccination-Heplisav™ compared with Engerix-B(®) vaccine in adults.Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study.German travelers' preferences for travel vaccines assessed by a discrete choice experiment.Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative GQuality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection.Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893.Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis.Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative GroupImpact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or aboveAdjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trialDevelopment of adjuvanted recombinant zoster vaccine and its implications for shingles preventionCost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States
P50
Q30669465-E9715971-3DBB-42C3-A278-28555A89B411Q30683663-19D32962-D696-43C2-80AF-061FEE2FA9ACQ32067201-6849FF24-7E85-45DE-BBEC-4006FC4C0682Q33331752-0EA4D37F-7E49-4BBF-B4BD-73143A3BDE60Q33333132-F3333F31-3850-47B0-A874-0A5E1AA70395Q33502766-63DAD1DE-073F-4733-8860-14E60A99C9E5Q34160545-EF89143B-348C-4866-9680-772734136590Q34644867-DEF529FA-C86E-422B-91CA-E3B13B2D686CQ35721473-D507D3CF-7368-429B-B2F0-B3D55BB0EA8CQ36257901-93268448-5284-444F-8552-A55F90B0A216Q36886976-02260EFD-31F0-4787-90C3-D2211354714AQ37299565-34005C0A-29E8-40FF-90F3-A4A5B36B2CA3Q37473335-1E972F30-E7C3-458D-B118-15396642385FQ37522192-44903E7C-A927-4CFB-B98D-CC7CDFBBD1EDQ38678770-E7A21D7A-1B6A-491B-962A-EB960A5E1B24Q40032366-1E89F284-FE4C-48A0-8979-4BFF660DDDDEQ43704841-C9F67B66-6E20-4B17-9E5D-0C8ED018CAEEQ44410659-C6FC03A2-A9AD-47FD-B3BE-557D81F0C85EQ47116379-CED39B87-45BD-402A-81E7-B827CEC18A09Q47141395-721220BD-21B3-44C5-AE02-4AA2C3DD08BBQ47670834-75E7F3C9-AF78-4D89-9431-6ED72A20D37FQ48281457-D019D1FE-FF62-41A3-9C08-B97CEE30FCE3Q48520607-AA4F633D-C91C-438D-83BB-CE0FE236A181Q48629888-D5E468C9-8589-454E-9187-F0A3D93E934FQ48716517-B9ABC317-5871-45E3-9C30-F414915AF27AQ49066055-D35AF26B-D492-4B32-A405-F368077DC55CQ49165377-D4DAFD10-5145-4123-9A9D-E0B3C748F43CQ50023555-E2352807-DAE1-4122-AE74-C43C24786BBFQ50049598-EAFE70C5-22DD-4FC0-942D-DAF498E40852Q51096264-2214C770-1D8E-4F3D-A804-76A9E9D25726Q53190270-C89325E0-DBF0-4261-9BE7-8A7B3316E4B1Q53403756-128E1FF3-CF23-41AA-81F1-16830E2C9906Q53524255-934F6B3F-3A81-4B82-87DD-AF4EF6AEDC2CQ53558519-304B7A99-8D08-4465-B652-7159ABB2200CQ54230925-97B97B15-1EC8-481E-BB13-ED1069670A23Q56562473-CF8068C9-1AE8-4DD5-B778-4C40B74F3560Q57034394-10CF3DCA-58A5-43A0-A50A-42F0B157CE88Q57758612-45E090A8-E625-4369-A9B6-CD269290B14EQ59356381-E8A6181E-C2E0-4495-A603-5414A8DF653DQ59356687-AD45538E-9C58-45AB-A516-1330E24D1E4D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Desmond Curran
@ast
Desmond Curran
@en
Desmond Curran
@es
Desmond Curran
@nl
Desmond Curran
@sl
type
label
Desmond Curran
@ast
Desmond Curran
@en
Desmond Curran
@es
Desmond Curran
@nl
Desmond Curran
@sl
prefLabel
Desmond Curran
@ast
Desmond Curran
@en
Desmond Curran
@es
Desmond Curran
@nl
Desmond Curran
@sl
P106
P1153
7102435363
P31
P496
0000-0002-7423-0111